Amphora Discovery Corporation, a newly-launched chemical genomics firm, has appointed Jennings Worley to lead its ion channel drug discovery program.

The program, which includes the application of “micro-fluidics,” novel gene experessions and electrophysiology therapies, is used to discover new drugs that target ion channels, according to a statement released by Amphora.

Martin Haslanger, president and chief executive officer of Amphora, says: “Jennings brings twelve years of pharmaceutical drug discovery experience to Amphora as well as significant depth of ion channel biology which will enable our ion channel chemical genomics program.”

Worley was integral to the development of GlaxoSmithKline’s ion channel drug discovery program, Amphora says. He spent 12 years with GSK.